Tag: mail

Statkraft, Europe's largest producer of renewable energy, will further strengthen its core competitive advantages by prioritising its flexible hydropower fleet in the Nordics, industry-leading market operations – and solar, wind and battery activities in Europe and South America. 

Statkraft, Europas største produsent av fornybar energi, vil styrke kjerneaktivitetene ytterligere ved å prioritere vannkraft i Norden, bransjeledende markedsoperasjoner, samt utbygging og drift av solkraft, vindkraft og batterier i Europa og Sør-Amerika.

KUALA LUMPUR, MALAYSIA, June 18, 2025 (GLOBE NEWSWIRE) -- TMD Energy Limited (the “Company” or “TMDEL”) (NYSE American: TMDE), together with its subsidiaries is a Malaysia and Singapore based services provider engaged in integrated bunkering services which involves ship-to-ship transfer of marine fuels, ship management services and vessel chartering services, today announced the Company has entered into a Memorandum of Agreement (“MOA”) with bioenergy firm Double Corporate Sdn Bhd (“Double Corporate”) to explore a strategic collaboration for the EU and Asia market.

EfTEN United Property Fund earned a net profit of 170 thousand euros in May and 1,32 million euros in the first five months of 2025 (compared to 357 thousand euros in the same time last year). In May, the fund made a cash distribution to investors in the amount of 1.47 million euros, or 57-euro cents per unit. As a result, the fund's net asset value (NAV) decreased by 4,4% and was 11,02 euros per unit at the end of May. Without the distribution the NAV of EfTEN United Property Fund would have increased by 0,6% in May.

Cardiff, United Kingdom – 18 June 2025 – Draig Therapeutics (“Draig”), a clinical-stage company aiming to transform the treatment of neuropsychiatric diseases, today launches from stealth having raised a total of $140 million (£107 million) in the last nine months. The oversubscribed Series A financing was led by Access Biotechnology, with participation from Canaan Partners, SR One, Sanofi Ventures, Schroders Capital along with seed investors SV Health Investors, which co-founded the company, and ICG.

～Record Participation for SBC Medical. 22 doctors Present Insights in Their Respective Fields～

TARRYTOWN, N.Y., June 17, 2025 (GLOBE NEWSWIRE) -- Medtech Products Inc., a Prestige Consumer Healthcare Inc. company (“Medtech” or “Company”), is voluntarily recalling five lots of Little Remedies® Honey Cough Syrup (the “Product”) due to the presence of Bacillus cereus and loss of shelf-stability. Bacillus cereus (B. cereus) can cause two types of food-borne illnesses. One type is characterized by nausea, vomiting, and stomach cramps that can start 1 to 6 hours after eating or drinking contaminated food. The second type can cause stomach cramps and diarrhea that can start 8 to 16 hours after eating or drinking contaminated food. Diarrhea may be a small volume or profuse and watery. Although healthy individuals may suffer only short-term illness, exposure to high levels of foodborne B. cereus can cause death.

REDWOOD CITY, Calif., June 17, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, announced today that it has commenced an underwritten public offering of shares of its common stock and accompanying warrants to purchase shares of its common stock (or pre-funded warrants in lieu thereof) and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock and accompanying warrants to purchase shares of its common stock (or pre-funded warrants in lieu thereof). In addition, Biomea intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%) of the shares of common stock and pre-funded warrants offered in the public offering. All of the shares, pre-funded warrants and accompanying common stock warrants to be sold in the proposed offering are to be sold by Biomea.

New York, NY, June 17, 2025 (GLOBE NEWSWIRE) -- Mixed Martial Arts Group Limited (NYSE American: MMA) (“MMA” or the “Company”), announced today the pricing of an underwritten public offering of 6,578,948 ordinary shares (or pre-funded warrants to purchase ordinary shares in lieu thereof) at a public offering price of $0.76 per share (the “Offering”). The aggregate gross proceeds to MMA from the Offering are expected to be approximately $5.0 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by MMA. The Offering is expected to close on June 18, 2025, subject to the satisfaction of customary closing conditions.